協和新藥股份有限公司

Update：2025/12/24

Industries

Biotechnology Biopharma Genetics Oncology Pharmaceutical

Add to Favorites Edit

About

Financials

Patent

News

Main Industry

Biotechnology

Founded Year

2014

Unified Business No.

24758757

Status

Closed

Number of Employees

Total Paid-in Capital

0 (NT$)

Location of Company

Taiwan

Website

Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.

Exclusive content for members

Members-only content. Please log in to access.

Similar Companies

Asgene Inc.

Biotechnology Biopharma Genetics Life Science Oncology

Taiwan Bio-Manufacturing Corporation

TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.

Biotechnology Biopharma Genetics Manufacturing Pharmaceutical

Rephlmmune Biotechnology Inc.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and

Biotechnology Biopharma Genetics Oncology Therapeutics

ARCE THERAPEUTICS, INC.

ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)

Biotechnology Biopharma Genetics Oncology Therapeutics